BioNexus Gene Lab Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BGLC research report →
Price Chart
About the company
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn.
- CEO
- Su-Leng Tan
- IPO
- 2021
- Employees
- 19
- HQ
- Kuala Lumpur, WP, MY
Get TickerSpark's AI analysis on BGLC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.64M
- P/E
- -0.58
- PEG
- 0.06
- P/S
- 2.80
- P/B
- 0.26
- EV/EBITDA
- -0.40
- Div Yield
- 0.00%
- Gross Margin
- -1.47%
- Op Margin
- -470.22%
- Net Margin
- -463.08%
- ROE
- -36.50%
- ROIC
- -38.50%
Latest fiscal year · YoY change
- Revenue
- $7.42M-21.9%
- Gross Profit
- $1.09M-15.8%
- Op Income
- $-3,158,450
- Net Income
- $-2,984,607-86.7%
- EPS
- $-1.61-78.9%
- OCF Growth
- +17.7%
- FCF Growth
- +23.8%
- 52W High
- $4.97
- 52W Low
- $0.62
- 50D MA
- $1.15
- 200D MA
- $1.81
- Beta
- 2.20
- RSI (14)
- 27
- Avg Volume
- 6.70K
No earnings-call transcripts are available for BGLC yet.
- Free Float
- 64.4%
- Shares Outstanding
- 2.42M
- Float Shares
- 1.56M
of shares held by institutions
3 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ubs Group AG | 306 | ▲ 205 |
| Caitong International Asset Management Co., Ltd | 137 | ▲ 136 |
| Tower Research Capital LLC (Trc) | 12 | ▲ 12 |
| Jpmorgan Chase & Co | 2 | ▲ 2 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 26 | Tan Lee Su-Leng | other | 338,709 |
| Aug 13, 26 | Yap Chee Keong | other | 32,258 |
| Aug 13, 26 | Bin Abdul Hamid Muhammad Azrul | other | 32,258 |
| Aug 13, 26 | Chong Set Fui | other | 96,774 |
| Aug 13, 26 | Low Jook Yuen | other | 16,129 |
| Nov 28, 25 | FIDELION DIAGNOSTICS PTE. LTD. | other | 0 |
| Aug 15, 23 | Tan Lee Su-Leng | other | 0 |
| Dec 11, 23 | Bin Abdul Hamid Muhammad Azrul | other | 0 |
| Mar 7, 22 | Yap Chee Keong | other | 0 |
| Jun 17, 25 | Low Jook Yuen | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BGLC coverage
Recent articles, reports, and earnings notes.
No research on BGLC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BGLC report →BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
globenewswire.com · Nov 3
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
globenewswire.com · Oct 30
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
globenewswire.com · Oct 7
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
globenewswire.com · Oct 5
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
globenewswire.com · Jul 28
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
globenewswire.com · May 29
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
globenewswire.com · Mar 11
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
globenewswire.com · Feb 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.